Raza S - Search Results

1

Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.

Li S, Fu J, Lu C, Mapara MY, Raza S, Hengst U, Lentzsch S. Li S, et al. Among authors: raza s. Mol Cancer Ther. 2016 Apr;15(4):711-9. doi: 10.1158/1535-7163.MCT-15-0798. Epub 2016 Mar 3. Mol Cancer Ther. 2016. PMID: 26939700

2

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.

Raza S, Safyan RA, Lentzsch S. Raza S, et al. Curr Cancer Drug Targets. 2017;17(9):846-857. doi: 10.2174/1568009617666170214104426. Curr Cancer Drug Targets. 2017. PMID: 28201976 Review.

3

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S. Raza S, et al. Ther Adv Hematol. 2017 Feb;8(2):55-70. doi: 10.1177/2040620716680548. Epub 2016 Dec 9. Ther Adv Hematol. 2017. PMID: 28203342 Free PMC article. Review.

4

The Critical Role of Imaging in the Management of Multiple Myeloma.

Raza S, Leng S, Lentzsch S. Raza S, et al. Curr Hematol Malig Rep. 2017 Jun;12(3):168-175. doi: 10.1007/s11899-017-0379-9. Curr Hematol Malig Rep. 2017. PMID: 28317080 Review.

5

Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Edwards CV, Gould J, Langer AL, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, Wall J, Solomon A, Lentzsch S. Edwards CV, et al. Among authors: raza s. Amyloid. 2017 Mar;24(sup1):58-59. doi: 10.1080/13506129.2017.1292900. Amyloid. 2017. PMID: 28434347 Clinical Trial. No abstract available.

6

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Leng S, Bhutani D, Raza S, Assal A, Pan S, Hu J, Wei A, Mapara M, Lentzsch S. Leng S, et al. Among authors: raza s. Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5. Blood Cancer J. 2020. PMID: 32015343 Free PMC article. Clinical Trial. No abstract available.

7

Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Dima D, Hughes M, Orland M, Ullah F, Goel U, Anwer F, Raza S, Mazzoni S, Bhutani D, Williams L, Lentzsch S, Samaras C, Valent J, Chakraborty R, Khouri J. Dima D, et al. Among authors: raza s. Amyloid. 2024 Sep;31(3):195-201. doi: 10.1080/13506129.2024.2366806. Epub 2024 Jul 2. Amyloid. 2024. PMID: 38956891

8

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

Lin CH, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, Bader A, Samaras C, Valent J, Khouri J, Anwer F, Raza S, Dima D. Lin CH, et al. Among authors: raza s. Int J Mol Sci. 2024 Jun 4;25(11):6192. doi: 10.3390/ijms25116192. Int J Mol Sci. 2024. PMID: 38892379 Free PMC article. Review.

9

Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.

Jaberi-Douraki M, Xu X, Dima D, Ailawadhi S, Anwer F, Mazzoni S, Valent J, Habib MH, Riviere JE, Raza S. Jaberi-Douraki M, et al. Among authors: raza s. Blood Cancer J. 2024 Dec 20;14(1):223. doi: 10.1038/s41408-024-01206-4. Blood Cancer J. 2024. PMID: 39706832 Free PMC article.

10

Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles.

Imperial R, Ahmed Z, Toor OM, Erdoğan C, Khaliq A, Case P, Case J, Kennedy K, Cummings LS, Melton N, Raza S, Diri B, Mohammad R, El-Rayes B, Pluard T, Hussain A, Subramanian J, Masood A. Imperial R, et al. Among authors: raza s. Mol Cancer. 2018 Dec 21;17(1):177. doi: 10.1186/s12943-018-0923-9. Mol Cancer. 2018. PMID: 30577807 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,067 results

Search Page

Filters